Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

IMI European Lead Factory — democratizing access to high-throughput screening

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 21, 245-246 (2022)



The European Lead Factory has received support from the Innovative Medicines Initiative (IMI) Joint Undertaking under grant agreement no. 115489, resources of which are composed of financial contribution from the EU’s Seventh Framework Programme and EFPIA companies' in-kind contribution. This project has also received funding from the IMI-2 Joint Undertaking (JU) under grant agreement no. 806948. The JU receives support from the EU’s Horizon 2020 research and innovation programme, the EFPIA and Medicines for Malaria Venture (MMV).


This communication reflects the views of the authors and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.

Updates & Corrections

  • Correction 24 January 2022: Andrew D. Pannifer was missing from the list of consortium authors, and this has been corrected.


  1. Macarron, R. et al. Impact of high-throughput screening in biomedical research. Nat. Rev. Drug Discov. 10, 188–195 (2011).

    Article  PubMed  Google Scholar 

  2. Brem, J. et al. Imitation of β-lactam binding enables broad-spectrum metallo-β-lactamase inhibitors. Nat. Chem. (2021).

  3. Goutopoulos, A. et al. Abstract LB-295: Discovery of potent selective oral ACSS2 inhibitors for the treatment of acetate avid tumors. Cancer Res. 80, (2020).

  4. Mullard, A. 2020 FDA approvals. Nat. Rev. Drug Discov. 20, 85–90 (2021).

    Article  PubMed  Google Scholar 

Download references

Competing Interests

The following authors are employed by companies as indicated in more detail by their affiliations: P.S.J., S.B., S.P.M, A.M., S.P.V.H., S.H., S.V.B., H.V.D.H., V.M.L., D.B., J.H., S.J., E.O., T.V., J.B., R.H.A.F., F.L., J.S.B.D.V., P.M.K.-V., V.J.M.N., K.M.O., T.R., C.P., O.E., G.P., P.B.S., J.-Y. O., D.R., S.M.K., P.W.M.R., H.V.V., E.J.A.V.W., C.V., P.N., K.B.S., L.T., D.F., M.J., N.A.B.-B., H.H., C.K., H.M., T.D., B.L., F.R.O., D.H., G.J., C.P., A.P., D.T., J.D., D.D., C.V., D.V.B. and A.D.P.

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links